This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $81.57 in the latest trading session, marking a -1.53% move from the prior day.
The Zacks Analyst Blog Highlights Visa, Novo Nordisk, Medtronic, Shopify and Colgate-Palmolive
by Zacks Equity Research
Visa, Novo Nordisk, Medtronic, Shopify and Colgate-Palmolive are included in this Analyst Blog.
Top Stock Reports for Visa, Novo Nordisk & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Visa Inc. (V), Novo Nordisk A/S (NVO) and Medtronic plc (MDT).
Boston Scientific's (BSX) POLARx System Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $83.12, moving +0.22% from the previous trading session.
Medtronic (MDT) Rides on Strong Global Growth, New Launches
by Zacks Equity Research
Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $82.94 in the latest trading session, marking a +0.85% move from the prior day.
Here's Why You Should Invest in Medtronic (MDT) Stock Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $88.96 in the latest trading session, marking a -0.44% move from the prior day.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $87.65, moving -0.45% from the previous trading session.
The Zacks Analyst Blog Highlights Alibaba, Medtronic, Schlumberger, Cisco Systems and Moody's
by Zacks Equity Research
Alibaba, Medtronic, Schlumberger, Cisco Systems and Moody's are part of the Zacks top Analyst Blog.
Top Research Reports for Alibaba, Medtronic & Schlumberger
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Medtronic plc (MDT) and Schlumberger Limited (SLB).
Beat the Market Like Zacks: Shopify, Medtronic, Oracle in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $86.07, marking a -0.92% move from the previous day.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $86.77 in the latest trading session, marking a +0.47% move from the prior day.
Medtronic's (MDT) MiniMed 780G System Favored by New Data
by Zacks Equity Research
Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.
Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.
Top Analyst Reports for Costco, Salesforce & Thermo Fisher Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Salesforce, Inc. (CRM) and Thermo Fisher Scientific Inc. (TMO).
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.